Suppr
超能文献

Acceptable changes in quality attributes of glycosylated biopharmaceuticals.

作者信息

Schiestl Martin, Stangler Thomas, Torella Claudia, Cepeljnik Tadej, Toll Hansjörg, Grau Roger

出版信息

Nat Biotechnol. 2011 Apr;29(4):310-2. doi: 10.1038/nbt.1839.

DOI:10.1038/nbt.1839

PMID:21478841

Abstract

摘要

相似文献

Acceptable changes in quality attributes of glycosylated biopharmaceuticals.

Nat Biotechnol. 2011 Apr;29(4):310-2. doi: 10.1038/nbt.1839.

An industry perspective on plasma-derived products.

Dev Biol (Basel). 2004;118:31-5.

Current and future approaches to ensure the viral safety of biopharmaceuticals.

Dev Biol (Basel). 2004;118:17-29.

Am J Health Syst Pharm. 2008 Jul 15;65(14 Suppl 6):S2-8. doi: 10.2146/ajhp080210.

Clin Pharmacol Ther. 2010 Mar;87(3):257-61. doi: 10.1038/clpt.2009.112.

Darbepoetin alfa administration in patients with non-Hodgkin lymphoma and chemotherapy-induced anemia receiving (±R) CHOP.

Hematology. 2013 Jan;18(1):26-9. doi: 10.1179/1607845412Y.0000000033. Epub 2012 Sep 12.

Darbepoetin alfa: a novel erythropoiesis-stimulating protein.

Drugs Today (Barc). 2003 Jul;39(7):477-95. doi: 10.1358/dot.2003.39.7.799441.

Comparative Assessment of the Effect of Hyper-glycosylation on the Pattern and Kinetics of Degradation of Darbepoetin Alfa using a Stability-Indicating Orthogonal Testing Protocol.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jan 1;1072:405-414. doi: 10.1016/j.jchromb.2017.10.057. Epub 2017 Nov 4.

Current legal, regulatory, and scientific implications of biosimilars. Introduction.

Am J Health Syst Pharm. 2008 Jul 15;65(14 Suppl 6):S1. doi: 10.2146/ajhp080209.

Optimizing the use of erythropoietic agents-- pharmacokinetic and pharmacodynamic considerations.

Nephrol Dial Transplant. 2002;17 Suppl 5:66-70. doi: 10.1093/ndt/17.suppl_5.66.

引用本文的文献

Comprehensive Physico-chemical and Functional Similarity Assessment Study of RGB-14-P and RGB-14-X Drug Products as Proposed Biosimilars to Denosumab Reference Products.

BioDrugs. 2025 Sep;39(5):697-724. doi: 10.1007/s40259-025-00738-w. Epub 2025 Aug 6.

Scientific Justification and Policy Recommendations to the US Food and Drug Administration for Waiving Comparative Efficacy Studies.

Pharmaceuticals (Basel). 2025 May 23;18(6):779. doi: 10.3390/ph18060779.

Characterization of Biosimilar Monoclonal Antibodies and Their Reference Products Approved in Japan to Reveal the Quality Characteristics in Post-approval Phase.

BioDrugs. 2025 May 7. doi: 10.1007/s40259-025-00722-4.

PET Imaging Expedites Detection of Aberration in the Humanization of an Annexin A1 Targeting Antibody.

Pharmaceuticals (Basel). 2025 Feb 21;18(3):295. doi: 10.3390/ph18030295.

"Small is beautiful" - Examining reliable determination of low-abundant therapeutic antibody glycovariants.

J Pharm Anal. 2024 Oct;14(10):100982. doi: 10.1016/j.jpha.2024.100982. Epub 2024 Apr 26.

Soft-sensor model development for CHO growth/production, intracellular metabolite, and glycan predictions.

Front Mol Biosci. 2024 Oct 22;11:1441885. doi: 10.3389/fmolb.2024.1441885. eCollection 2024.

Sci Rep. 2024 Sep 6;14(1):20861. doi: 10.1038/s41598-024-71352-z.

In situ production and secretion of proteins endow therapeutic benefit against psoriasiform dermatitis and melanoma.

Proc Natl Acad Sci U S A. 2023 Dec 26;120(52):e2313009120. doi: 10.1073/pnas.2313009120. Epub 2023 Dec 18.

A Critical Analysis of the FDA's Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity.

Pharmaceuticals (Basel). 2023 Nov 2;16(11):1556. doi: 10.3390/ph16111556.

Temperature Upshifts in Mammalian Cell Culture: A Suitable Strategy for Biosimilar Monoclonal Antibodies?

Bioengineering (Basel). 2023 Sep 30;10(10):1149. doi: 10.3390/bioengineering10101149.

本文引用的文献

Understanding and circumventing resistance to anticancer monoclonal antibodies.

MAbs. 2009 May-Jun;1(3):222-9. doi: 10.4161/mabs.1.3.8292. Epub 2009 May 24.

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.

Pharmacol Ther. 2008 Feb;117(2):244-79. doi: 10.1016/j.pharmthera.2007.10.001. Epub 2007 Oct 26.

Mechanisms of killing by anti-CD20 monoclonal antibodies.

Mol Immunol. 2007 Sep;44(16):3823-37. doi: 10.1016/j.molimm.2007.06.151.

Analysis of lysine clipping of a humanized Lewis-Y specific IgG antibody and its relation to Fc-mediated effector function.

J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1-2):250-6. doi: 10.1016/j.jchromb.2007.01.024. Epub 2007 Jan 26.

Determination of the origin of the N-terminal pyro-glutamate variation in monoclonal antibodies using model peptides.

Biotechnol Bioeng. 2007 Jun 15;97(3):544-53. doi: 10.1002/bit.21260.

Characterizing biological products and assessing comparability following manufacturing changes.

Nat Biotechnol. 2004 Nov;22(11):1383-91. doi: 10.1038/nbt1030.

Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin.

Exp Hematol. 2003 Apr;31(4):290-9. doi: 10.1016/s0301-472x(03)00006-7.

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity.

J Biol Chem. 2002 Jul 26;277(30):26733-40. doi: 10.1074/jbc.M202069200. Epub 2002 May 1.

Development and characterization of novel erythropoiesis stimulating protein (NESP).

Br J Cancer. 2001 Apr;84 Suppl 1(Suppl 1):3-10. doi: 10.1054/bjoc.2001.1746.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

Acceptable changes in quality attributes of glycosylated biopharmaceuticals.

作者信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译